News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Diabetes Drug Data Revealed Amid Hostile Takeover



5/25/2012 7:51:39 AM

GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that’s part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI), its partner on the drug. Glaxo will present data from two of eight late-stage studies, dubbed Harmony 6 and Harmony 7, of the once-weekly drug albiglutide ahead of the American Diabetes Association’s annual meeting next month. Abstracts of those studies will be posted on the ADA website today.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES